PHARNEXT: After 6 years of total trial time, data from the o

New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on

Related Keywords

Schwann , Baden Wüberg , Germany , Canada , United States , Paris , France General , France , Gewinn Nur , Fabreguettes Leib , Shahram Attarian , Schwartz , Neuromuscular Diseases Reference Centers , Rare Diseases Network , University Hospital La Timone , Open Label Phase , Overall Neuropathy Limitation Scale , Charcot Marie Tooth Disease Type , Overall Neuropathy Limitations Scale , Neuromuscular Diseases , Diseases Network , Lead Investigator , First Double Blind Phase , Open Label Extension , Total Trial , High Dose , Low Dose , Label Extension , Meter Walk Test , Quantified Muscular Testing , Patient Global Impression , Charcot Marie Tooth Neuropathy Score , Euronext Growth , Presse Financi , Pharnext , After , Tears , Total , Trial , Dime , Data , Rom , Pen , Label , Leo , Consistent , Song , Term , Benefit , Xt3003 , Charcot , Marie , Tooth , Disease , Type , Mt1a ,